CLAIMS

1. Use of a non-immunosuppresive, cyclophilin-binding cyclosporin in the manufacture of a medicament for treating or preventing ischemic brain damage, traumatic brain or spinal cord injury or stroke.

- 2. A method for the treatment or the prevention of ischemic brain damage or traumatic brain or spinal cord injury in a patient suffering from or at risk of suffering from such a disease or condition, comprising administering to said patient an effective amount of a non-immunosuppresive, cyclophilin-binding cyclosporin.
- 3. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppresive, cyclophilin-binding cyclosporin is a compound of formula (A):

-MeBmt-αAbu-B-C-Val-MeLeu-Ala-(*D*)Ala-MeLeu-MeLeu-MeVal
1 2 3 4 5 6 7 8 9 10 11 (A)

wherein B is an amino acid residue of formula (B):

wherein

a denotes the bond to the αAbu residue in position 2;

b denotes the bond to the residue C in the 4 position;

Alk represents straight- or branched-chain alkylene containing from 2-6 carbon atoms or cycloalkylene containing from 3-6 carbon atoms; and

R represents

a carboxy or alkyloxycarbonyl radical;

a radical -NR₁R₂,

in which

R₁ and R₂ are the same or different and represent hydrogen, alkyl, C₂₋₄alkenyl, C₃₋₆cycloalkyl, phenyl (optionally substituted by halogen, alkoxy, alkoxycarbonyl, amino, alkylamino or dialkylamino) or a benzyl or saturated or unsaturated heterocyclyl radical containing 5- or 6-ring atoms and 1-3 heteroatoms, or

R₁ and R₂ form, together with the nitrogen atom to which they are attached, a saturated or unsaturated heterocycle containing 4-6 ring atoms and optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur and optionally substituted by alkyl, phenyl or benzyl;

a radical of formula:

wherein

R₁ and R₂ are as defined above;

R₃ represents hydrogen or an alkyl radical; and

n is a whole number from 2-4; and

alkyl denotes straight- or branched-chain alkyl containing from 1-4 carbon atoms;

C is MeLeu or 4-hydroxy-MeLeu;

and the pharmaceutically acceptable salts thereof.

4. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppresive, cyclophilin-binding cyclosporin is a compound of formula (I):

in which

W is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;

X is αAbu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R is Sar or (D)-MeAla;

Y is MeLeu, γ-hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Me Tyr, MeTyr(O-PO(OH)₂), Mealle or MeaThr or Pro;

Z is Val, Leu, N-Alk-Val or N-Alk-Leu, wherein Alk represents Me or Me substituted by vinyl optionally substituted by phenyl, or an N, S or O heteroaryl containing 6 ring members, or phenyl optionally substituted by halogen; and

- Q is MeLeu, γ-hydroxy-MeLeu or MeAla.
- 5. A use according to Claim 1 or a method according to Claim 2, in which the nonimmunosuppresive, cyclophilin-binding cyclosporin is a compound selected from the group comprising:
- a) [dihydro-MeBmt]¹-[γ-hydroxy-MeLeu]⁴-Ciclosporin;
- b) [MeVal]4-Ciclosporin;
- c) [Melle]4-Ciclosporin;
- d) [MeThr]4-Ciclosporin;
- e) [γ-hydroxy-MeLeu]⁴-Ciclosporin;
- f) [Nva]²-[γ-hydroxy-MeLeu]⁴-Ciclosporin;
- g) $[\gamma$ -hydroxy-MeLeu]⁴- $[\gamma$ -hydroxy-MeLeu]⁶-Ciclosporin;
- h) [MeVal]⁵-Ciclosporin;
- i) [MeOThr]²-[(D)MeAla]³-[MeVal]⁵-Ciclosporin;
- j) [8'-hydroxy-MeBmt]1-Ciclosporin;
- k) [MeAla]6-Ciclosporin;
- I) [DMeAla]³-[MeTyr(OPO(OH)₂)]⁴-Ciclosporin;
- m) [N-Benzyl-Val]⁵-Ciclosporin;
- n) [N-5-Fluoro-Benzyl-Val]⁵-Ciclosporin;
- o) [N-Allyl-Val]5-Ciclosporin;
- p) [N-3-Phenyl-Allyl-Val]⁵-Ciclosporin;
- q) [Pro]⁴-Ciclosporin or
- r) [γ-hydroxy-MeLeu]9-Ciclosporin.

6. A use according to Claim 1 or a method according to Claim 2, in which the non-immunosuppresive, cyclophilin-binding cyclosporin is [Melle]⁴-Ciclosporin or [γ-hydroxy-MeLeu]⁴-Ciclosporin.